Metformin NDMA Settlement?

Recall Alert and Settlement: Understanding the Metformin NDMA Controversy

In 2019, the FDA announced that a generic form of the diabetes medication metformin contained high levels of N-nitrosodimethylamine (NDMA), a possible carcinogen [1]. To address the issue, several companies involved in the manufacturing and distribution of generic metformin reached a settlement agreement.

Why are companies challenging this patent?

There are ongoing challenges and disputes surrounding the metformin patent, primarily related to the settlement agreement and potential generic alternatives. However, a major concern revolves around the issue of NDMA contamination in generic metformin.

How has the settlement impacted the pharmaceutical industry?

The settlement aimed to resolve the issue and prevent shortages of metformin while addressing concerns about NDMA contamination. However, it has also sparked discussions about patent disputes, generic competition, and consumer safety.

What happens if patients experience side effects or adverse reactions?

Patients taking metformin affected by the NDMA contamination are advised to consult their healthcare providers. In some cases, patients may need to switch to a different medication or undergo further testing.

When are the patent exclusivities set to expire?

The patent exclusivities for metformin vary depending on the product and manufacturer, but many generic versions of metformin are already available [2]. As patents expire, more generic options will enter the market.

Difference between the original and generic versions of metformin

The generic versions of metformin were found to contain high levels of NDMA, leading to the recall and settlement. Meanwhile, the original brand-name version of metformin, produced by certain pharmaceutical companies, has not been linked to NDMA contamination [3].

Who makes the reformulated metformin without NDMA?

Several pharmaceutical companies have reformulated metformin to eliminate NDMA contamination. As part of the settlement agreement, manufacturers have committed to producing NDMA-free generic metformin [4].

When will exclusivity expire for the re-manufactured product?

As more manufacturers enter the market with reformulated, NDMA-free metformin, the patent exclusivities will eventually expire [5]. This will allow other companies to produce and sell generic versions of the medication.

Can biosimilars enter before patent expiry?

Under certain circumstances, biosimilars can enter the market before patent expiry, especially if they meet strict regulatory requirements. This could potentially accelerate the availability of NDMA-free metformin to consumers [6].

Sources:

[1] FDA (2019). FDA announces it has found NDMA in some metformin products. https://www.fda.gov/news-events/press-announcements/fda-announces-it-has-found-ndma-some-metformin-products

[2] DrugPatentWatch.com. (2022). Metformin https://www.drugpatentwatch.com/drug/1139/metformin

[3] FDA (2020). Update on NDMA in Metformin. https://www.fda.gov/drugs/drug-safety-and-availability/update-ndma-metformin

[4] Bloomberg Law (2020). Settlement Reached Over Metformin Recall. https://news.bloomberglaw.com/pharmalinks/settlement-reached-over-metformin-recall

[5] Generic Phamacia (2020). Exclusivity and Patent Information for Metformin. https://www.genericpharma.com/metro/metformin.html

[6] IQVIA (2023). Biosimilars and Patent Exclusivities. https://www.iqvia.com/insights/the-pursuit-of-innovation/biosimilars-and-patent-exclusivities